These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31392987)

  • 1. Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.
    Grüschow S; Athukoralage JS; Graham S; Hoogeboom T; White MF
    Nucleic Acids Res; 2019 Sep; 47(17):9259-9270. PubMed ID: 31392987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems.
    Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF
    Methods Enzymol; 2019; 616():191-218. PubMed ID: 30691643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6.
    Garcia-Doval C; Schwede F; Berk C; Rostøl JT; Niewoehner O; Tejero O; Hall J; Marraffini LA; Jinek M
    Nat Commun; 2020 Mar; 11(1):1596. PubMed ID: 32221291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of cyclic oligoadenylate synthesis in a type III CRISPR system.
    Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF
    Elife; 2018 Jul; 7():. PubMed ID: 29963983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
    Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF
    Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate.
    McMahon SA; Zhu W; Graham S; Rambo R; White MF; Gloster TM
    Nat Commun; 2020 Jan; 11(1):500. PubMed ID: 31980625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptation in CRISPR-Cas Systems.
    Sternberg SH; Richter H; Charpentier E; Qimron U
    Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. If You'd Like to Stop a Type III CRISPR Ribonuclease, Then You Should Put a Ring (Nuclease) on It.
    Mo CY; Marraffini LA
    Mol Cell; 2018 Nov; 72(4):608-609. PubMed ID: 30444997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Isothermal Method for Sensitive Detection of Mycobacterium tuberculosis Complex Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas12a Cis and Trans Cleavage.
    Xu H; Zhang X; Cai Z; Dong X; Chen G; Li Z; Qiu L; He L; Liang B; Liu X; Liu J
    J Mol Diagn; 2020 Aug; 22(8):1020-1029. PubMed ID: 32470556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heavily Armed Ancestors: CRISPR Immunity and Applications in Archaea with a Comparative Analysis of CRISPR Types in Sulfolobales.
    Zink IA; Wimmer E; Schleper C
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33172134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity.
    Athukoralage JS; McMahon SA; Zhang C; Grüschow S; Graham S; Krupovic M; Whitaker RJ; Gloster TM; White MF
    Nature; 2020 Jan; 577(7791):572-575. PubMed ID: 31942067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23.
    Grüschow S; McQuarrie S; Ackermann K; McMahon S; Bode BE; Gloster TM; White MF
    Nucleic Acids Res; 2024 Apr; 52(6):2761-2775. PubMed ID: 38471818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
    Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
    Elife; 2020 Jun; 9():. PubMed ID: 32597755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Csm6 ribonuclease by cyclic nucleotide binding: in an emergency, twist to open.
    McQuarrie S; Athukoralage JS; McMahon SA; Graham S; Ackermann K; Bode BE; White MF; Gloster TM
    Nucleic Acids Res; 2023 Oct; 51(19):10590-10605. PubMed ID: 37747760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.
    Niewoehner O; Garcia-Doval C; Rostøl JT; Berk C; Schwede F; Bigler L; Hall J; Marraffini LA; Jinek M
    Nature; 2017 Aug; 548(7669):543-548. PubMed ID: 28722012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Card1 nuclease provides defence during type III CRISPR immunity.
    Rostøl JT; Xie W; Kuryavyi V; Maguin P; Kao K; Froom R; Patel DJ; Marraffini LA
    Nature; 2021 Feb; 590(7847):624-629. PubMed ID: 33461211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate.
    Athukoralage JS; Rouillon C; Graham S; Grüschow S; White MF
    Nature; 2018 Oct; 562(7726):277-280. PubMed ID: 30232454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.
    Han W; Stella S; Zhang Y; Guo T; Sulek K; Peng-Lundgren L; Montoya G; She Q
    Nucleic Acids Res; 2018 Nov; 46(19):10319-10330. PubMed ID: 30239876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity.
    Barrangou R; Marraffini LA
    Mol Cell; 2014 Apr; 54(2):234-44. PubMed ID: 24766887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.